Descripción de la empresa
Heartflow, Inc. operates within the healthcare sector, specifically serving the health information services industry by delivering non-invasive diagnostic solutions for coronary artery diseases in the United States and globally. The company's core business revolves around its HeartFlow Platform, which leverages artificial intelligence and computational fluid dynamics to generate personalized three-dimensional models of a patient's heart derived from a single imaging study. This medical technology approach aims to streamline the diagnosis and management process for cardiovascular conditions without the need for invasive procedures. As of the latest available data, the company holds a market capitalization of $2.30 billion and employs 843 individuals across its operations. The reported annual revenue of $176.03 million, combined with a substantial market cap, indicates that the market assigns a significant premium to the company's proprietary technology and its position in the expanding digital health diagnostics space. These valuation metrics suggest that investors are pricing in high future growth expectations, positioning the company as a major player relative to its peer group within the specialized health information services niche.
Salud financiera
The company reported a revenue of $176.03 million over the trailing twelve months, yet this generated a net income of -$116,791,000 and an EBITDA of -$62,626,000, highlighting a substantial gap between top-line growth and profitability. This disparity reveals a cost structure where operating expenses and research development investments are currently outweighing gross profits, a common characteristic in capital-intensive technology scaling phases. The free cash flow stands at -$30,882,376, indicating that the company is burning cash, which limits immediate financial flexibility for acquisitions or heavy capital expenditures without external funding. Despite the negative operating performance, the balance sheet maintains $176.79 million in cash against $22.05 million in debt, suggesting a highly liquid position with significant excess cash reserves. The debt-to-equity ratio is recorded at 7.34, a figure that, while indicating high leverage mathematically, must be viewed in the context of the company's massive cash hoard which effectively mitigates immediate solvency risks. The current ratio is a robust 5.20, signaling that the company possesses more than five times the current assets required to cover its short-term liabilities, reflecting excellent short-term liquidity management. Return on Equity is -111.4% and Return on Assets is -16.7%, metrics that demonstrate that management is currently generating negative returns on shareholder capital and total assets, reflecting the aggressive reinvestment strategy or operational losses typical of pre-profitability growth stages.
Evaluación de valoración
The valuation metrics present a complex picture with a P/E Ratio (TTM) listed as N/A due to negative earnings and a Forward P/E of -89.50, implying that the market expects earnings to turn positive in the future to justify the current share price. The price-to-book ratio is 7.62, indicating that the stock trades at a significant premium of roughly 7.6 times its book value, which reflects investor confidence in the intangible assets and intellectual property of the HeartFlow Platform. Alternative valuation multiples show a Price to Sales of 13.09 and an EV/EBITDA of -34.32, suggesting the market is valuing the company based on revenue potential rather than current cash generation or earnings power. Regarding trading range, the 52-week high is $41.22 and the 52-week low is $20.13; without a specific current price provided in the facts, the valuation context is defined by this wide trading band of $21.09. The beta is listed as N/A, meaning volatility data relative to the broader market is not disclosed in the available records, preventing a direct comparison of price sensitivity to market movements. These alternative metrics collectively suggest the market is willing to pay a high multiple for revenue growth, anticipating a structural shift from losses to profitability that would normalize these ratios significantly.
Growth & Income
Revenue growth for the trailing twelve months is 40.5%, demonstrating a rapid expansion in the top line, whereas earnings growth is N/A due to the absence of positive net income over the past year. Because the company is currently unprofitable, earnings are not growing faster than revenue in a traditional sense, but rather the company is prioritizing market capture and platform development over immediate profit realization. Heartflow does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that the company reinvests all available cash flow and retained earnings directly back into business operations and growth initiatives rather than distributing income to shareholders. This reinvestment strategy is essential for a firm in the health information services sector that requires continuous technological advancement and regulatory compliance to maintain its competitive edge. The overall growth and income profile is characterized by aggressive top-line expansion funded by internal cash reserves and external capital, with the expectation that future profitability will eventually emerge to support a transition toward dividend payments or share repurchases once the negative EBITDA and operating losses are resolved.